Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: Final report of a prospective clinical trial

Targeted Oncology

Volumn 9, Issue 2, 2014, Pages 145-153

  Kao, Johnny ^a   Chen, Chien Ting ^b   Tong, Charles C L ^c   Packer, Stuart H ^c   Schwartz, Myron ^d   Chen, Shu Hsia ^c   Sung, Max W ^c  

^a Good Samaritan Hospital Medical Center   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Image guided radiation therapy; Metastases; Oligometastases; Stereotactic body radiation therapy (SBRT); Sunitinib

Indexed keywords

ERLOTINIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIFE EXPECTANCY; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METABOLIC DISORDER; METASTASIS; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OLIGOMETASTASIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECOMMENDED DRUG DOSE; SKIN DISEASE; STEREOTACTIC BODY RADIATION THERAPY; STOMATITIS; THROMBOCYTOPENIA; THYROID METASTASIS; VOMITING; CHEMORADIOTHERAPY; CLINICAL TRIAL; KAPLAN MEIER METHOD; MULTIMODALITY CANCER THERAPY; NEOPLASM METASTASIS; PROCEDURES; RADIOSURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; RADIOSURGERY;

EID: 84902550806     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0280-y     Document Type: Article

References (33)

1. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8-10
2. Andrews DW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665-1672 (Pubitemid 38670323)
3. Patchell RA et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494-500 (Pubitemid 20067825)
4. Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378-382
5. Timmerman RD et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59(3):145-170
6. Lee MT et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585-1591
7. Milano MT et al (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112(3):650-658 (Pubitemid 351186206)
8. Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579-1584
9. Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572-1578
10. Salama JK et al (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14(16):5255-5259
11. Salama JK et al (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11):2962-2970
12. Milano MT, et al (2011) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys
13. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 4(2):86- 100
14. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884-896 (Pubitemid 350002890)
15. Karaman MWet al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26(1):127-132
16. Mauceri HJ et al (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394(6690):287-291 (Pubitemid 28335042)
17. Schueneman AJ et al (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63(14):4009-4016 (Pubitemid 36917920)
18. Ozao-Choy J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69(6):2514-2522
19. Ko JS et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148-2157
20. Tong CC et al (2012) Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One 7(6):e36979
21. Kao J et al (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115(15):3571-3580
22. Wahl RL et al (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
23. Milano MT et al (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3):878-886
24. Mehta N et al (2004) Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 25(6):1677-1683
25. Rusthoven KE et al (2009) Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48(4):578-583
26. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124 (Pubitemid 46089672)
27. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487-494
28. Postow MA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925-931
29. Kao J et al (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 77(1):12-19
30. Uematsu M et al (2001) Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 51(3):666- 670
31. Timmerman RD et al (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25(8):947-952 (Pubitemid 350002860)
32. Milano MT, Constine LS, Okunieff P (2008) Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 3:36
33. Gerszten PC et al (2004) CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery 55(1):89-98, discussion 98-9